Cognition Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cognition Therapeutics's earnings have been declining at an average annual rate of -15.5%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually.
Key information
-15.54%
Earnings growth rate
76.67%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | n/a |
| Return on equity | -57.12% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Cognition...We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Summary Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not outperform placebo on all rating scales over 3-6 months, raising concerns for future milestones and larger trials. Financial reliance on NIH grants poses risks, and ongoing trials in dementia with Lewy Bodies, Alzheimer's and dry AMD have the potential for further stock decline. Read the full article on Seeking AlphaIs Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Summary Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024. CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aβ oligomers. Preliminary data from the ongoing SHINE trial showed some interesting results, but were not consistent with other previous studies, raising caution about the upcoming data. At a ~$70 million market cap with about half of that cash, the topline readout could be a binary event for the stock. Read the full article on Seeking AlphaHere's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Cognition Therapeutics (NASDAQ:CGTX) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results in a normalization of the EEG patterns. The trial is enrolling 16 adults who will receive either CT1812 or placebo, the company said in a Sept. 27 press release. Cognition noted that the study is taking place at the Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center. The NIA, a division of the National Institutes of Health (NIH), awarded a $3.2M grant in 2020 to support the study and has now awarded $2.14M, the company added. CGTX +12.28% to $1.92 premarket Sept. 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
An analysis of biomarker data from Cognition Therapeutics' (NASDAQ:CGTX) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40. The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's. Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Revenue & Expenses Breakdown
How Cognition Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 0 | -20 | 10 | 33 |
| 31 Dec 25 | 0 | -23 | 11 | 37 |
| 30 Sep 25 | 0 | -28 | 11 | 34 |
| 30 Jun 25 | 0 | -33 | 11 | 42 |
| 31 Mar 25 | 0 | -33 | 12 | 42 |
| 31 Dec 24 | 0 | -34 | 12 | 42 |
| 30 Sep 24 | 0 | -34 | 13 | 45 |
| 30 Jun 24 | 0 | -31 | 13 | 45 |
| 31 Mar 24 | 0 | -29 | 14 | 42 |
| 31 Dec 23 | 0 | -26 | 14 | 37 |
| 30 Sep 23 | 0 | -23 | 13 | 32 |
| 30 Jun 23 | 0 | -23 | 14 | 29 |
| 31 Mar 23 | 0 | -24 | 14 | 29 |
| 31 Dec 22 | 0 | -21 | 13 | 30 |
| 30 Sep 22 | 0 | -24 | 17 | 29 |
| 30 Jun 22 | 0 | -22 | 14 | 25 |
| 31 Mar 22 | 0 | -19 | 12 | 21 |
| 31 Dec 21 | 0 | -16 | 10 | 19 |
| 30 Sep 21 | 0 | -12 | 5 | 16 |
| 30 Jun 21 | 0 | -10 | 4 | 16 |
| 31 Mar 21 | 0 | -9 | 4 | 14 |
| 31 Dec 20 | 0 | -12 | 5 | 13 |
Quality Earnings: CGTX is currently unprofitable.
Growing Profit Margin: CGTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CGTX is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.
Accelerating Growth: Unable to compare CGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-4.8%).
Return on Equity
High ROE: CGTX has a negative Return on Equity (-57.12%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/01 10:04 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cognition Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| null null | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |